The administration of selective ERβ activators are currently preferred owing to controversy over the increased risk of breast cancer, endometrial cancer, and thromboembolism in the action of ERα [15,16,41,42,43,44,45,46,47,48,49]. This evidence concerns the gene ESR1 and breast cancer.